News

The Pharma Letter7m
In the UK, Eisai and Biogen seek to extend Alzheimer’s treatment flexibility
UK regulators are set to review a proposed label update for Eisai (TYO: 4523) and Biogen’s (Nasdaq: BIIB) Alzheimer’s drug ...
The Pharma Letter18m
AstraZeneca continues legal battles over Forxiga in Russia
The Russian drugmaker Akrikhin has filed a lawsuit against UK pharma major AstraZeneca (LSE: AZN) to the Moscow Intellectual ...